thy, cerebellar ataxia, and isolated myopathy [Emmanuele et al., 2012] . In most cases, the family history suggests an autosomal recessive mode of inheritance. Since 2006, mutations in 7 genes, encoding components closely related with the CoQ 10 biosynthetic pathway, have been associated with human CoQ 10 deficiency ( table 1 ) . However, in the preponderance of patients with CoQ 10 deficiency, it has not been possible to identify the underlying genetic cause . The genetic diagnosis of CoQ 10 deficiency is complicated by the fact that the CoQ 10 biosynthetic pathway has yet to be fully elucidated in humans, and the possibility arises that the cause of the deficit may result from pathogenic mutations in genes not directly related to CoQ 10 synthesis [Emmanuele et al., 2012] .
The purpose of this article is to critically review the current biochemical methods used in the diagnosis of human CoQ 10 deficiency and to indicate the most appropriate tissues for this evaluation.
Methods Used to Determine Tissue CoQ 10 Status
The most common laboratory procedures used for diagnosis of CoQ 10 deficiency are based on high-pressure liquid chromatography with ultraviolet (HPLC-UV) or electrochemical (HPLC-ED) detection systems. Other procedures, such as tandem-mass spectrometry, have been employed for tissue CoQ 10 assessment; however, this method will not be discussed further in this article and the reader is referred to the review by Barshop and Gangoiti [2007] which discusses this analytical procedure. Although it is possible to determine the reduced (ubiquinol) and oxidized forms of CoQ 10 concomitantly by HPLC-ED analysis, diagnostically, the determination of total tissue CoQ 10 status is sufficiently accurate to detect human CoQ 10 deficiencies. Simultaneous measurement of both reduced and oxidized forms of CoQ 10 usually requires a complex pre-analytical management of samples, and chromatographically, this is more complicated than the measurement of total CoQ 10 . Furthermore, the propensity of ubiquinol to oxidise to CoQ 10 unless frozen immediately at -80 ° C may detract from the clinical utility of this determination [Molyneux et al., 2008] . Therefore, the simultaneous assessment of both reduced and oxidised forms of CoQ 10 is probably more suitable for research purposes rather than for clinical diagnosis. However, in appropriately handled tissue samples the ratio of ubiquinol:CoQ 10 has been used as a marker of oxidative stress [Niklowitz et al., 2004; Kaya et al., 2012] .
In the following paragraphs, details of the HPLC methods employed to determine tissue CoQ 10 status in the laboratories of the authors will be outlined. 
HPLC-UV Conditions
Total tissue CoQ 10 status is quantified by reversephase HPLC with UV detection at 275 nm according to the method of Duncan et al. [2005] . CoQ 10 is separated on a HPLC column (Techsphere ODS 5 μm, 150 × 4.6 mm). The mobile phase consists of ethanol:methanol:60% perchloric acid; 700: 300: 1.2 to which 7 g of sodium perchlorate are added [Boitier et al., 1998 ]. The flow rate is maintained at 0.7 ml/min. Ubiquinone species are detected at 275 nm. This HPLC method has been used to determine the CoQ 10 status of skeletal muscle and blood mononuclear cells which were prepared and extracted according to the method of Duncan et al. [2005] .
HPLC-ED Conditions
The total CoQ 10 concentration is quantified by reverse-phase HPLC with electrochemical detection (Coulochem II, ESA, Mass., USA) according to a previously reported procedure [Montero et al., 2008] . Briefly, CoQ 9 and CoQ 10 are separated in a nucleosil C-18 column Infant with severe fatal CoQ 10 deficiency; Duncan et al. [2009] (5 μm, 25 × 0.4 cm, Teknokroma, Barcelona, Spain). The mobile phase consists of 20 mM of lithium perchlorate in ethanol/methanol (40/60). Electrochemical detector cells were set to -600 mV (conditioning cell, Model 5021) and +600 mV (analytical cell, Model 5010). This HPLC method has been employed to assess the CoQ 10 status of plasma, skeletal muscle, and fibroblasts ( fig. 2 ) which were prepared and extracted according to the method of Montero et al. [2008] .
Internal Standards
A major difficulty encountered when assessing CoQ 10 status in tissue is the lack of commercially available nonphysiological internal standards (IS). In most cases coenzyme Q 9 is the IS of choice [Okamoto et al., 1988] . Unfortunately, as a result of dietary contamination and synthesis by intestinal microorganisms, CoQ 9 has been detected in human tissue and plasma samples contributing up to 2-7% of the total ubiquinone pool [Weber et al., 1997] . To avoid the possible influence of endogenous ubiquinones when evaluating tissue CoQ 10 status, the nonphysiological ubiquinones, di-ethoxy-CoQ 10 [Edlund, 1988] and di-propoxy-CoQ 10 , have been employed as IS in these determinations.
Tissue Assessment
Plasma, Blood Mononuclear Cells, and Platelet Assessment Clinical assessment of CoQ 10 deficiency is generally based on plasma measurements, and the reference interval established for plasma CoQ 10 status appears to range from 0.5 to 1.7 μ M [Molyneux et al., 2008] . Plasma CoQ 10 levels are also monitored following supplementation therapy to assess absorption and bioavailability of CoQ 10 formulations. Plasma CoQ 10 levels as high as 10.7 μ M have been reached following supplementation with solubilised formulations of ubiquinol [Bhagavan and Chopra, 2007] . Higher than 'normal' levels of plasma CoQ 10 appear requisite to facilitate tissue uptake and allow transfer across the blood brain barrier, although these levels may [Bhagavan and Chopra, 2007] . In Parkinson's disease, plasma CoQ 10 levels of 4.6 μ M were reported by Shults et al. [2002] to be the most efficacious in slowing functional decline in patients. In contrast, a plasma level of 2.8 μ M showed the highest therapeutic benefit in the treatment of congestive heart disease patients [Belardinelli et al., 2006] . Gender does not appear to influence plasma CoQ 10 status [Molyneux et al., 2005] ; however, the effect of age upon plasma CoQ 10 levels is as yet uncertain, with studies reporting both a positive correlation with age and others finding no age effects [Miles et al., 2004; Duncan et al., 2005] . Plasma CoQ 10 status is influenced by both dietary supply and hepatic biosynthesis [Hargreaves et al., 2005] . This is in contrast to other tissues which are dependent upon de novo biosynthesis [Kalen et al., 1987] . The effect of diet is of particular importance, since CoQ 10 has a relatively long circulatory half-life (approx. 24 h), and dietary intake may contribute up to 25% of the total amount of plasma CoQ 10 [Weber et al., 1997] . Plasma CoQ 10 status is highly dependent upon the concentration of lipoproteins which are the major carriers of CoQ 10 in the circulation, with approximately 58% of total plasma CoQ 10 being associated with low-density lipoprotein or LDL fraction [Karlsson et al., 1992; McDonnell and Archbold, 1996] . Therefore, in view of its dependence upon both dietary intake and lipoprotein concentration, plasma CoQ 10 status may not truly reflect tissue levels . It has been suggested that plasma CoQ 10 levels should be expressed as a ratio to either total plasma cholesterol or LDL cholesterol in order to be of diagnostic value [Kontush et al., 1997; Tomasetti et al., 1999] . Furthermore, expressing plasma CoQ 10 as a ratio to total cholesterol appears to exclude any influence of age on this parameter [Wolters and Hahn, 2003; Molyneux et al., 2005] .
Assessment of blood mononuclear cells has been suggested as an alternative surrogate to evaluate endogenous CoQ 10 status . Mononuclear cells are easily isolated from EDTA/Li-Heparin blood, and the CoQ 10 status of these cells has been reported to correlate with that of skeletal muscle . Blood mononuclear cells are also reported to reflect changes in cellular status following supplementation [Turunen et al., 2004] . This is illustrated by the patient described in the study of Duncan et al. [2005] who was found to have a CoQ 10 deficiency in blood mononuclear cells (20 pmol/ mg of protein: reference interval 37-133 pmol/mg). However, following CoQ 10 supplementation at 300 mg/day for 2 months, the mononuclear cell CoQ 10 status of the patient increased to 42 pmol/mg, and this was accompanied by an improvement in mobility; the patient went from being a 'bottom shuffler' to being able to walk upright with the aid of assistance. Platelets have also been used as surrogates to evaluate endogenous CoQ 10 levels in clinical studies [Shults et al., 1997; Mortensen et al., 1998 ]. Furthermore, the CoQ 10 status of platelets was also found to increase following CoQ 10 supplementation indicating these cell fragments may also be used to monitor the effect of CoQ 10 supplementation on endogenous levels [Niklowitz et al., 2004] .
Skeletal Muscle
Skeletal muscle is generally considered as the tissue of choice for CoQ 10 assessment, and this tissue has been used in diagnosis of CoQ 10 deficiency since the first cases of this deficiency were reported by Ogasahara et al. [1989] . However, in view of the importance of this tissue in the diagnosis of CoQ 10 deficiency, there appears to be no universally accepted units in which to represent skeletal muscle CoQ 10 status, and therefore it is difficult to compare reference ranges between laboratories ( table 2 ). As is shown in table 2 , skeletal muscle CoQ 10 status can be represented in either units of μg/g fresh weight of tissue or as pmol/mg of protein (nmol/g of protein). Interestingly, although HPLC-UV and HPLC-ED detection methods were used to determine skeletal muscle CoQ 10 status in the studies reported by Rahman et al. [2001] and Montero et al. [2008] , respectively, the reference ranges reported in these studies are markedly similar. In the study by Montero et al. [2008] , a patient was described in whom a decreased skeletal muscle CoQ 10 status was suspected in view of a severe reduction in the activities of the ETC CoQ 10 -dependent enzymes, complexes II-III (succinate: cytochrome c reductase; EC. 1.3.5.1 + 1.10.2.2) and I-III (NADH: cytochrome c reductase; EC 1.6.5.3 + 1.10.2.2). However, the patient was found to have a normal level of skeletal muscle CoQ 10 when related to protein (125 nmol/g; reference values: 110-480 nmol/g). When the muscle CoQ 10 content was related to citrate synthase (CS) activity, the mitochondrial marker enzyme [Selak et al., 2000] , evidence of a CoQ 10 deficiency, was apparent (1.16 nmol/CS units; reference values 2.68-8.47 nmol/CS units). A possible explanation for this observation offered by the authors was the possibility that the high degree of muscle injury the patient was experiencing [rhabdomyolysis and elevated plasma creatine kinase levels (250,000 UI; reference values 50-250 UI)] may have resulted in a depletion of skeletal muscle protein. Therefore, when the CoQ 10 status was related to total muscle protein content, this may result in a 'false-negative' result. Since approximately 50% of cellular CoQ 10 is present in the mitochondria [Ernster and Dallner, 1995] , expressing muscle CoQ 10 status in relation to CS activity may have important diagnostic value ( table 2 ). This is especially important in mitochondrial myopathies where excessive proliferation of mitochondria has been reported in muscle [DiMauro, 2004] and therefore expressing CoQ 10 to CS activity which takes into account that the mitochondrial enrichment of the sample may highlight evidence of a deficiency which may not be identifiable if CoQ 10 status is solely related to total protein.
Decreased activity of either ETC complex I-III and/or complex II-III is also indicative of a CoQ 10 deficiency as the activity of these linked enzymes is dependent upon endogenous CoQ 10 [Rahman et al., 2001] . Furthermore, the study by Montero et al. [2008] has suggested that complex II-III activity may be a more sensitive marker of a diminution in CoQ 10 status than that of complex I-III. However, normal levels of complex I-III or II-III activity do not exclude a decrease in muscle CoQ 10 status as has previously been observed in patients with the ataxic phenotype of CoQ 10 deficiency [Lamperti et al., 2003] . In view of the essential role ubiquinol plays in pyrimidine synthesis [Lopez et al., 2006] , mitochondrial DNA depletion syndrome may also be associated with a decrease in CoQ 10 status as has been reported by Montero et al. [2009] . Therefore, the assessment of muscle CoQ 10 status in patients who present with multiple ETC deficiencies should not be discouraged. Furthermore, in view of the association between mitochondrial DNA mutations and muscle coenzyme Q 10 deficiency, assessment of muscle HPLC-tandem mass spectrometry 2.0-2.8 (2.4) nmol/CS units Buján et al. [2013] Data is presented as range (mean) values. Regarding the reference values in muscle and fibroblasts, most authors report consistent reference intervals, although noticeable differences are present in others. In view of this, the use of validated protocols together with an external quality control program seems necessary to minimize such differences. a CS = Citrate synthase. b These data are reported as ng/mg of muscle mitochondrial protein. CoQ 10 status should be considered in addition to the determination of ETC enzyme activities in patients with suspected mitochondrial disease [Sacconi et al., 2010] . Decreased glycerol 3-phosphate dehydrogenase and/or dihydroorotate cytochrome c reductase activity may also indicate evidence of decreased muscle CoQ 10 levels as these enzymes have been reported to be especially sensitive to perturbations in CoQ 10 status [Rotig et al., 2000] .
Diagnosis of

Fibroblasts
Assessment of fibroblast CoQ 10 status should also be considered in the diagnosis of CoQ 10 deficiency. Published reference ranges for fibroblast CoQ 10 status are shown in table 2 . In view of the suggested tissue specificity of CoQ 10 deficiency, a normal level of CoQ 10 in fibroblasts does not exclude a deficit in CoQ 10 status in other tissues [Ogasahara et al., 1989] . Indeed, normal levels of fibroblast CoQ 10 have been reported in patients with genetically confirmed defects in CoQ 10 biosynthesis [Lagier-Tourenne et al., 2008] . In contrast, however, fibroblast assessment has been used to reveal evidence of a CoQ 10 deficiency in a patient with a normal muscle CoQ 10 status [Montero et al., 2008] . Fibroblasts also provide a means of assaying CoQ 10 biosynthesis by studying the incorporation of 14 C-p-hydroxybenzoate, 3 H-mevalonate, and/or 3 H-decaprenyl-pyrophosphate into CoQ 10 [Lopez et al., 2006; Quinzii et al., 2006] . These radiolabelled incorporation studies can be used to confirm a deficiency in CoQ 10 biosynthesis, identify the position of the defect in the biosynthetic pathway in some cases, as well as to discriminate between primary and secondary CoQ 10 deficiencies.
Cerebral Spinal Fluid
In view of the preponderance of neurological dysfunction associated with CoQ 10 deficiency [Mancuso et al., 2010] , the ability to assess cerebral CoQ 10 status would be of considerable diagnostic value. Cerebral spinal fluid (CSF) is considered the appropriate surrogate to assess cerebral CoQ 10 status. However, in view of the low levels of CoQ 10 detected in CSF with HPLC-UV, detection would be insufficiently sensitive for this analysis . Tentative reference ranges for CSF CoQ 10 levels of 1.18-4.91 nM established from a patient cohort aged 9-18 years, n = 15 [Artuch et al., 2004] and 5.7-9 nM established from a patient cohort aged 0.1-22 years, n = 17 [Duberley et al., 2012] , respectively, have been reported. The discrepancies in these ranges may in part result from the different analytical techniques and sample preparations employed for this determination. In the study by Artuch et al. [2004] , CSF samples were filtered by passing through a 10,000-NMWL column prior to analysis by HPLC-EC detection. In contrast, tandem spectrometry was employed to determine the CoQ 10 status in unfiltered CSF in the study by Duberley et al. [2012] . A further factor, which may also have contributed to this disparity, is the different ages of the 'disease control' patients used to establish these reference ranges. Although Isobe et al. [2010] reported no correlation between age and CSF CoQ 10 status, this study was undertaken solely in adults aged 65.8 ± 12.4 years (mean ± SD), and CSF was not investigated from children. Therefore, in order to establish a more reliable and robust reference interval for CSF CoQ 10 status, further studies are required that evaluate the effects of age, gender, as well as the rostral-caudal gradient upon CSF levels of this ubiquinone.
Discussion/Conclusion
The actual prevalence of human CoQ 10 deficiency is at present unknown, but it is suspected that this condition is under-diagnosed . This is compounded by the lack of specialist centres which are able to determine tissue CoQ 10 status together with the extreme clinical heterogeneity of this condition . It is recommended that the CoQ 10 status is determined in the muscle biopsies of all patients with suspected mitochondrial disease. Once evidence of a CoQ 10 deficiency is detected, further studies will be required to elucidate the underlying cause of this defect. Genetic investigations and radiolabelled biosynthetic studies in fibroblasts may help to distinguish between primary or secondary causes of the deficiency. However, in a number of patients with CoQ 10 deficiency it has not been possible to elucidate the underlying cause of the defect .
Since muscle biopsies may not always be available, there is a need for a less invasive means to assess tissue CoQ 10 status. Although there are some concerns over the diagnostic value of plasma CoQ 10 levels, platelet and blood mononuclear cell determinations may offer an alternative means for this assessment.
It has been suggested that there may be tissue specific isoenzymes in the CoQ 10 biosynthetic pathway; therefore the CoQ 10 status of one tissue may not reflect that of another [Ogasahara et al., 1989] . Since neurological dysfunction is a constant clinical feature in CoQ 10 deficiency syndromes, although some defects may be expressed in muscle or peripheral tissue, other defects (such as those in cerebral CoQ 10 biosynthesis) may not be expressed and may remain undiagnosed. The ability to accurately assess CSF CoQ 10 status may therefore enhance the diagnosis yield of patients with neurological dysfunction and previously undiagnosed cerebral CoQ 10 deficiency. In view of the differences in the tissue of choice for CoQ 10 assessment, units in which CoQ 10 is expressed and the reference intervals used for this diagnosis between laboratories a more unified approach is required for monitoring patients and their treatment. The establishment of an external quality control (Ex-QC) scheme for the measurement of tissue CoQ 10 status is suggested for laboratories offering this clinical diagnostic service. At present, a trial Ex-QC scheme is running between laboratories in the UK and Spain and, if successful, will be offered on a more global scale.
